Announcements Trials

Browse Landscape

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 19 Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Hormone-sensitive Prostate Cancer 1

Interventions

Surveys and Questionnaires 18 Blood Specimen Collection 16 Specimen Handling 12 Observation 6 Magnetic Resonance Spectroscopy 6 Surgical Procedures, Operative 5 Radiotherapy 5 trastuzumab deruxtecan 4 ribociclib 4 darolutamide 4 Standard of Care 4 Patient Reported Outcome Measures 4 Letrozole 4 Data Collection 4 Cryosurgery 4 Breath Tests 4 Tomography, X-Ray Computed 3 Radiation 3 Neoadjuvant Therapy 3 Magnetic Resonance Imaging 3 Biopsy 3 Anastrozole 3 lorlatinib 2 cemiplimab 2 atezolizumab 2 Ultrasonography 2 Trastuzumab 2 Staining and Labeling 2 Restraint, Physical 2 Positron-Emission Tomography 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × apalutamide × 30 days × Clear all

NCT05901649 2026-05-08

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡